ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 1324

Similar Negative Effects of Fatigue on Physical Activity in Persons with Rheumatoid Arthritis and Healthy Controls: A Patient-Control Study
Abstract Number: 1325

Plasma Matrix Metalloproteinases and Heart Failure Outcomes in Rheumatoid Arthritis
Abstract Number: 1326

Association Between Physical Function and Nutritional Status in Rheumatoid Arthritis Patients
Abstract Number: 1327

Systematic Review of Mobility in Rheumatoid Arthritis with Digitally Measured Objective Assessment
Abstract Number: 1328

Mortality Trends of Hypertension in Patients with Rheumatoid Arthritis in the United States (1999–2020)
Abstract Number: 1329

Relationship Between Circulating Bacterial Small RNAs, Methotrexate Response, and Microbiome in New Onset Rheumatoid Arthritis
Abstract Number: 1330

Sex and reproductive stage modify the role of endogenous estrogens on coronary atherosclerosis in rheumatoid arthritis and differences reflect effects on inflammation and cholesterol metabolism
Abstract Number: 1331

Anti-beta-2-glycoprotein-1 IgA antibodies facilitate macrophage cholesterol loading and influence coronary atherosclerosis progression in a dose-dependent manner in rheumatoid arthritis
Abstract Number: 1332

Mid‐Infrared Spectroscopy for Enhanced Diagnosis of Rheumatic Diseases
Abstract Number: 1333

Assessment of lipid abnormalities after initiation of a JAK inhibitor in rheumatoid arthritis in clinical practice
Abstract Number: 1334

Cardiac Biomarkers and Prediction of Major Cardiovascular Events in Rheumatoid Arthritis: Results from the ESPOIR Cohort
Abstract Number: 1335

Chest x-Ray and pulmonary function tests are not sensitive for screening intertitial lung disease in reumatoid arthritis
Abstract Number: 1336

Effectiveness of new initiators of tofacitinib and other biologic/targeted synthetic DMARDs in patients with rheumatoid arthritis
Abstract Number: 1337

The Association Between Glucagon-Like Peptide-1 Receptor Agonist and Rheumatoid Arthritis: A Population-Based Case Control Study
Abstract Number: 1338

Short-Chain Fatty Acids and Their Gut Microbial Metabolic Pathways Distinguish Rheumatoid Arthritis in Discordant Monozygotic Twins

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].